Business Context and Reporting Period
Company: Oculis Holding AG (Oculis)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Oculis is a late clinical-stage biopharmaceutical company headquartered in Zug, Switzerland, with operations in the U.S. and Iceland. The company focuses on developing innovative therapeutics for ophthalmic and neuro-ophthalmic diseases. It has no products approved for commercial sale and has not generated any revenue from product sales to date.
Key Financial Metrics
| Metric (CHF thousands) | 2024 | 2023 |
|---|---|---|
| Revenue | 0 | 0 |
| Grant Income | 686 | 883 |
| Research & Development Expenses | (52,083) | (29,247) |
| General & Administrative Expenses | (21,807) | (17,487) |
| Operating Loss | (73,204) | (80,714) |
| Net Loss | (85,777) | (88,802) |
| Cash, Cash Equivalents & Short-Term Investments | 98,663 | 91,651 |
| Accumulated Losses | (285,557) | (199,780) |
Note: All figures are in Swiss Francs (CHF) unless otherwise noted. The company reported a net loss of CHF 85.8 million for 2024 compared to CHF 88.8 million for 2023.
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses decreased by 9.4% to CHF 73.9 million in 2024 from CHF 81.6 million in 2023. This decrease was primarily driven by the absence of a one-time CHF 34.9 million "Merger and listing expense" recorded in 2023 related to the Business Combination.
- R&D Expenses: Increased by 78.1% to CHF 52.1 million, driven by the advancement of Phase 3 trials for OCS-01 (DIAMOND-1 and DIAMOND-2), the Phase 2b RELIEF trial for Licaminlimab (OCS-02), and the Phase 2 ACUITY trial for Privosegtor (OCS-05).
- Finance Result: The net finance result worsened to a loss of CHF 12.7 million in 2024 from CHF 8.0 million in 2023. This was largely due to a CHF 15.5 million fair value loss on warrant liabilities (compared to CHF 3.4 million in 2023) driven by an increase in the company's share price.
- Liquidity: Cash and short-term financial assets increased to CHF 98.7 million as of December 31, 2024, up from CHF 91.7 million in 2023, supported by a Registered Direct Offering in April 2024.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- Cash Runway: Management believes existing cash, cash equivalents, and short-term financial assets, combined with proceeds from a February 2025 underwritten offering (CHF 90.1 million), are sufficient to fund operations for at least the next 12 months.
- Clinical Milestones:
- OCS-01: Preparing for New Drug Application (NDA) submission in Q1 2025 for inflammation and pain following ocular surgery. Phase 3 DIAMOND trials for Diabetic Macular Edema (DME) are ongoing.
- Privosegtor (OCS-05): Announced positive topline results from the Phase 2 ACUITY trial for acute optic neuritis in January 2025. FDA IND clearance received.
- Licaminlimab (OCS-02): Announced positive topline results from the Phase 2b RELIEF trial for Dry Eye Disease (DED) in June 2024. Aligned with FDA on a precision medicine development path.
Key Risks and Contingencies
- Capital Requirements: The company has incurred significant losses since inception and expects to continue doing so. It will require substantial additional funding to complete clinical development and commercialization. There is no assurance that additional capital will be available on acceptable terms.
- Clinical Trial Risks: Drug development is highly uncertain. The company faces risks regarding the success of ongoing Phase 3 trials, regulatory approval timelines, and potential safety issues. A third-party administrative error in August 2024 caused the closure of the Phase 3 OPTIMIZE-2 trial for OCS-01.
- Regulatory Pathways: OCS-01 relies on the Section 505(b)(2) regulatory pathway; failure to qualify could significantly delay approval and increase costs.
- Intellectual Property: The company relies on licenses from third parties (Novartis for OCS-02, Accure for OCS-05). Termination of these agreements or failure to meet milestones could impair development.
- Warrant Liabilities: The company has significant warrant liabilities (CHF 19.9 million as of Dec 31, 2024) that fluctuate with the stock price, creating volatility in reported net loss.
Important Facts for Investor Verification
- Revenue Status: Verify that the company has zero product revenue and relies entirely on financing and grants.
- Cash Position: Confirm the impact of the February 2025 underwritten offering (CHF 90.1 million) on the total cash balance, as this occurred after the reporting period end.
- Non-Cash Losses: Note that the reported net loss includes significant non-cash items, specifically the CHF 15.5 million fair value adjustment on warrant liabilities and share-based compensation.
- Clinical Trial Status: Monitor the progress of the DIAMOND Phase 3 trials for OCS-01 and the regulatory submission timeline for the post-surgical inflammation indication.
- License Obligations: Review the potential future milestone payments owed to Novartis (up to CHF 87.8 million) and Accure (up to CHF 101.4 million) upon successful development and commercialization.